Amphastar Pharmaceuticals Inc (AMPH) stock has fallen 12.92% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
Amphastar Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AMPH!
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With AMPH Stock Today?
Amphastar Pharmaceuticals Inc (AMPH) stock is trading at $32.55 as of 12:29 PM on Tuesday, Aug 9, a drop of -$5.20, or -13.77% from the previous closing price of $37.75. The stock has traded between $30.74 and $39.07 so far today. Volume today is high. So far 758,591 shares have traded compared to average volume of 319,917 shares.
More About Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Click Here to get the full Stock Report for Amphastar Pharmaceuticals Inc stock.